First effects of rising amyloid-β in transgenic mouse brain: Synaptic transmission and gene expression

Brain

Volumn 138, Issue 7, 2015, Pages 1992-2004

  Cummings, Damian M ^a   Liu, Wenfei ^a   Portelius, Erik ^b   Bayram, Sevinç ^c   Yasvoina, Marina ^a   Ho, Sui Hin ^a   Smits, Hélène ^a   Ali, Shabinah S ^a   Steinberg, Rivka ^a   Pegasiou, Chrysia Maria ^a   James, Owain T ^a   Matarin, Mar ^d,e   Richardson, Jill C ^f   Zetterberg, Henrik ^b,d   Blennow, Kaj ^b   Hardy, John A ^d   Salih, Dervis A ^a   Edwards, Frances A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Hitachi Europe Ltd   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid; gene expression; mouse; synaptic transmission

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ACTION POTENTIAL; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DENTATE GYRUS; DISEASE COURSE; ELECTROPHYSIOLOGICAL PROCEDURES; ENTORHINAL CORTEX; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; IMMUNOPRECIPITATION; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; RNA EXTRACTION; STRATUM LACUNOSUM MOLECULARE; STRATUM RADIATUM; SUBICULUM; SYNAPTIC TRANSMISSION; WHOLE CELL PATCH CLAMP; ANIMAL; DISEASE MODEL; DNA MICROARRAY; GENETICS; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATCH-CLAMP TECHNIQUES; PLAQUE, AMYLOID; SYNAPTIC TRANSMISSION; TRANSCRIPTOME;

EID: 84936802800     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv127     Document Type: Article

References (38)

1. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 2009; 12: 1567-76.
2. Brown TH, Johnston D. Voltage-clamp analysis of mossy fiber synaptic input to hippocampal neurons. J Neurophysiol 1983; 50: 487-507.
3. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008; 58: 42-51.
4. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011; 14: 69-76.
5. Daro E, van der Sluijs P, Galli T, Mellman I. Rab4 and cellubrevin define different early endosome populations on the pathway of transferrin receptor recycling. Proc Natl Acad Sci USA 1996; 93: 9559-64.
6. Dolev I, Fogel H, Milshtein H, Berdichevsky Y, Lipstein N, Brose N, et al. Spike bursts increase amyloid-beta 40/42 ratio by inducing a presenilin-1 conformational change. Nat Neurosci 2013; 16: 587-95.
7. Edwards FA, Konnerth A, Sakmann B, Takahashi T. A thin slice preparation for patch clamp recordings from neurones of the mammalian central nervous system. Pflugers Arch 1989; 414: 600-12.
8. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996; 119: 2001-7.
9. Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, Geyer MA, et al. Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res 2010; 209: 80-4.
10. Hannan AJ. Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity. Neuropathol Appl Neurobiol 2014; 40: 13-25.
11. Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, et al. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol 2008; 23: 67-76.
12. Howlett DR, Richardson JC. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 2009; 24: 83-100.
13. Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 2004; 1017: 130-6.
14. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
15. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5161-6.
16. Johnson RD, Schauerte JA, Chang CC, Wisser KC, Althaus JC, Carruthers CJ, et al. Single-molecule imaging reveals abeta42:abeta40 ratio-dependent oligomer growth on neuronal processes. Biophys J 2013; 104: 894-903.
17. Jolas T, Zhang XS, Zhang Q, Wong G, Del VR, Gold L, et al. Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neurobiol Dis 2002; 11: 394-409.
18. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function Neuron 2003; 37: 925-37.
19. Kumar RA, Sudi J, Babatz TD, Brune CW, Oswald D, Yen M, et al. A de novo 1p34.2 microdeletion identifies the synaptic vesicle gene RIMS3 as a novel candidate for autism. J Med Genet 2010; 47: 81-90.
20. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA and Ashe KH. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 2013; 136: 1383-98.
21. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol 2014; 220: 223-50.
22. Lundgren JL, Ahmed S, Winblad B, Gouras GK, Tjernberg LO, Frykman S. Activity-independent release of the amyloid beta-peptide from rat brain nerve terminals. Neurosci Lett 2014; 566: 125-30.
23. Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, et al. A Genome-wide gene expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Reports 2015; 10: 633-44.
24. McConlogue L, Castellano F, deWit C, Schenk D, Maltese WA. Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein. J Biol Chem 1996; 271: 1343-8.
25. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007; 55: 697-711.
26. Parsley SL, Pilgram SM, Soto F, Giese KP, Edwards FA. Enriching the environment of alphaCaMKIIT286A mutant mice reveals that LTD occurs in memory processing but must be subsequently reversed by LTP. Learn Mem 2007; 14: 75-83.
27. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010; 120: 185-93.
28. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 2007; 178: 18-28.
29. Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 2013; 43: 911-20.
30. Robins Wahlin TB, Byrne GJ. Personality changes in Alzheimer's disease: a systematic review. Int J Geriatr Psychiatry 2011; 26: 1019-29.
31. Sheng M, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol 2012; 4: pii a005777.
32. Somia NV, Schmitt MJ, Vetter DE, Van AD, Heinemann SF, Verma IM. LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci USA 1999; 96: 12667-72.
33. Stargardt A, Swaab DF, Bossers K. The storm before the quiet: neuronal hyperactivity and Abeta in the presymptomatic stages of Alzheimer's disease. Neurobiol Aging 2015; 36: 1-11.
34. Torres-Peraza JF, Engel T, Martin-Ibanez R, Sanz-Rodriguez A, Fernandez-Fernandez MR, Esgleas M, et al. Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. Brain 2013; 136: 1161-76.
35. Tozzi A, Sclip A, Tantucci M, de IA, Ghiglieri V, Costa C, et al. Region-and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. Neurobiol Aging 2015; 36: 123-3.
36. Walsh DM, Selkoe DJ. A beta oligomers-A decade of discovery. J Neurochem 2007; 101: 1172-84.
37. Wang Y, Sudhof TC. Genomic definition of RIM proteins: evolutionary amplification of a family of synaptic regulatory proteins. Genomics 2003; 81: 126-37.
38. Weidenhofer J, Scott RJ, Tooney PA. Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: effects of antipsychotic drugs. J Psychiatr Res 2009; 43: 282-90.